New Enobosarm / Ostarine trial is a success.

In this multi-center drug trial, enobosarm significantly improved physical function among patients with low testosterone, as well as normal hormone levels. Among the low testosterone group, physical function improved by 19 percent, while patients with normal hormone measurements increase their functional ability by 13 percent. At the study's start, 60 percent of patients had subnormal testosterone levels, lost more weight, and suffered greater declines in physical functioning than patients with normal hormone concentrations. This particular study examined a subset of this population, which comprised 93 male patients. Sixty percent of these men had low testosterone levels at the beginning of the trial. Investigators randomly assigned these participants to receive either 1 or 3 milligrams of oral enobosarm or placebo daily for 16 weeks. Since the trial was double-blinded, neither patients nor researchers knew which group was receiving the study drug versus placebo. At the study's beginning and end, investigators assessed patients' physical functioning using a stair-climbing test.